New vaccine support (NVS) for PNEUMO
GAVI’s support for new vaccines presents an opportunity for countries to not only implement vaccines that protect against diseases causing substantial morbidity and/or mortality, but also to build upon the vaccine investments in order to increase immunisation coverage rates, and strengthen routine immunisation services and primary health care systems. Pneumococcal vaccines can protect children from Streptococcus pneumoniae, which is the most common cause of severe pneumonia among children living in the developing world, and can also causes meningitis and sepsis. In line with WHO recommendations, GAVI support for pneumococcal vaccines is for routine infant immunisation. Two pneumococcal conjugate vaccines are currently available with GAVI support: a 10-valent (PCV10) and a 13-valent (PCV13).
- Project ID
47122-16-UGA-12B-X- Activity status
- 3 - Completion
- Aid type
- B02 - Core contributions to multilateral institutions
- % to Uganda
- 100.00
Organisations
- Funding
- The Global Alliance for Vaccination and Immunisation
- Extending
- World Health Organisation - core voluntary contributions account (for technical assitance)
- Accountable
- Federal States & Local Governments
- Implementing
- Federal States & Local Governments
- Extending
- United Nations Childrens Fund
Disbursements by fiscal year, quarter
| Fiscal year |
Fiscal quarter |
Value (USD) |
Uganda Value (USD) |
| 2016 |
Q4 |
-112,868.00 |
-112,868.00 |
| 2016 |
Q1 |
9,773,200.00 |
9,773,200.00 |
| 2015 |
Q4 |
9,774,200.00 |
9,774,200.00 |
| 2015 |
Q3 |
5,319,468.00 |
5,319,468.00 |
| 2015 |
Q2 |
4,898,600.00 |
4,898,600.00 |
Commitments by fiscal year, quarter
| Fiscal year |
Fiscal quarter |
Value (USD) |
Uganda Value (USD) |
| 2015 |
Q2 |
26,935,000.00 |
26,935,000.00 |
MTEF projections by fiscal year
| Fiscal year |
Value (USD) |
Uganda Value (USD) |
| 2016 |
13,467,500.00 |
13,467,500.00 |
| 2015 |
13,467,500.00 |
13,467,500.00 |
| CRS code |
% |
|
Infectious disease control
(12250)
|
100.0
|